Earnings Call Summary | BIOSTEM TECHNOLOGIES INC(BSEM.US) Q2 2024 Earnings Conference
Earnings Call Summary | BIOSTEM TECHNOLOGIES INC(BSEM.US) Q2 2024 Earnings Conference
The following is a summary of the BioStem Technologies, Inc. (BSEM) Q2 2024 Earnings Call Transcript:
以下是BioStem Technologies，Inc.（BSEM）2024年Q2業績會簡報摘要：
Financial Performance:
金融業績：
BioStem Technologies reported a record Q2 2024 revenue of $74.5 million, up considerably from the previous year's $1.6 million for the same period.
Gross profit for the quarter was $70.7 million, representing 95% of revenue.
Net income for Q2 2024 was $6.4 million, or $0.39 per share, a significant improvement from the net loss of $2.9 million, or $0.22 per share, in Q2 2023.
Operating expenses increased due to workforce expansion and partnership fees but were balanced by strong revenue growth.
BioStem Technologies報告2024年Q2記錄收入爲7450萬美元，大幅增長，比去年同期的160萬美元高出很多。
本季度毛利潤爲7070萬美元，佔收入的95%。
2024年Q2的淨利潤爲640萬美元，每股0.39美元，相比於2023年Q2的淨虧損290萬美元，每股0.22美元，有了顯著改善。
營業費用由於員工擴張和合作夥伴費用的增加而增加，但強勁的收入增長使其保持平衡。
Business Progress:
業務進展：
BioStem has initiated several strategic moves including plans to uplist to NASDAQ as a fully reporting entity, which is expected to enhance visibility and attract institutional investors.
Advanced in clinical trials, specifically the IRB approved study evaluating AmnioWrap2 in diabetic foot ulcers, aimed at demonstrating efficacy and securing expanded insurance coverage.
BioStem已啓動幾項戰略舉措，包括計劃將其作爲完全報告實體上市到納斯達克，預計這將提高其知名度並吸引機構投資者。
愛文思控股在臨床試驗中取得了進展，特別是IRB批准的評估AmnioWrap2在糖尿病足潰瘍中的療效和擴大保險覆蓋範圍的研究。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。